• In May 2026, Prestige Consumer Healthcare reported fourth-quarter sales of US$281.62 million versus US$296.52 million a year earlier, while net income rose to US$53.93 million and annual guidance outlined expected fiscal 2027 revenue of US$1.10–US$1.12 billion and GAAP diluted EPS of US$4.31–US$4.40.
• A few days later, its Dramamine brand introduced new travel-friendly Less Drowsy Powder stick packs and Nausea Chewables, broadening its nausea relief options across major US retailers and Amazon.
• We’ll now explore how the new Dramamine formats and Prestige’s higher quarterly profitability influence the company’s existing investment narrative.

Outshine the giants: these 13 early-stage AI stocks could fund your retirement.

Prestige Consumer Healthcare Investment Narrative Recap

To own Prestige Consumer Healthcare, you need to believe its portfolio of everyday health brands can keep generating solid cash flow despite supply chain issues and retail volatility. The latest quarter showed lower sales but higher earnings, suggesting cost discipline, while the new Dramamine formats are incremental rather than a clear fix for the near term risks around Clear Eyes supply recovery and retailer ordering patterns.

The most relevant recent announcement here is Prestige’s fiscal 2027 guidance for US$1.10–US$1.12 billion in revenue and GAAP diluted EPS of US$4.31–US$4.40. Set just days before the Dramamine launches, this outlook gives a reference point for how much impact, if any, these product extensions might have on reported results and on the company’s ability to manage margin pressures and retail demand swings.

But while new products and guidance support the story, investors should also be aware of the risk that ongoing supply chain volatility in eye care could...

Prestige Consumer Healthcare's narrative projects $1.2 billion revenue and $243.2 million earnings by 2029. This requires 4.2% yearly revenue growth and about a $56.7 million earnings increase from $186.5 million today.

Uncover how Prestige Consumer Healthcare's forecasts yield a $78.50 fair value, a 64% upside to its current price.

Exploring Other Perspectives

Before this news, the most optimistic analysts were assuming revenues near US$1.4 billion and earnings of about US$222.9 million by 2029, which paints a far more upbeat picture than the consensus view. As you weigh the new Dramamine launches against that kind of growth story and the execution risks around eye care capacity, it is worth considering how much your own expectations line up with these more aggressive forecasts or sit closer to the baseline.

Explore another fair value estimate on Prestige Consumer Healthcare - why the stock might be worth as much as 64% more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Prestige Consumer Healthcare research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Prestige Consumer Healthcare research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Prestige Consumer Healthcare's overall financial health at a glance.

Looking For Alternative Opportunities?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• This technology could replace computers: discover 28 stocks that are working to make quantum computing a reality.
• We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.